Publications

Frontiers in immunology

Distinct Patterns of Myeloid Cell Infiltration in Patients With hrHPV-Positive and hrHPV-Negative Penile Squamous Cell Carcinoma: The Importance of Assessing Myeloid Cell Densities Within the Spatial Context of the Tumor.

02-07-2021

Nature medicine

An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer.

01-07-2021

NPJ breast cancer

Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ.

22-03-2021

Nature medicine

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma.

01-02-2021

PloS one

Gene expression profiles of esophageal squamous cell cancers in Hodgkin lymphoma survivors versus sporadic cases.

22-12-2020

Nature medicine

Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial.

01-12-2020

Key Publication

Journal for immunotherapy of cancer

Comprehensive analysis of cutaneous and uveal melanoma liver metastases.

01-12-2020

European urology

FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?^†.

01-11-2020

Genetic epidemiology

Transcriptome-wide association study of breast cancer risk by estrogen-receptor status.

01-07-2020

Nature genetics

Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses.

01-06-2020

Melanoma research

Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM).

01-06-2020

Nature medicine

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.

01-04-2020

European journal of cancer (Oxford, England : 1990)

Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.

01-03-2020

The American journal of surgical pathology

Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCIS.

01-11-2019

Key Publication

The Lancet. Oncology

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.

01-07-2019

Nature communications

Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer.

15-04-2019

Blood

Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma.

07-03-2019

The Journal of urology

Concurrent Radiotherapy and Panitumumab after Lymph Node Dissection and Induction Chemotherapy for Invasive Bladder Cancer.

01-03-2019

Genome research

The circular RNome of primary breast cancer.

01-03-2019

Head & neck

HLA class II expression on tumor cells and low numbers of tumor-associated macrophages predict clinical outcome in oropharyngeal cancer.

01-02-2019

Nature

Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

01-02-2019

Gut

Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations.

01-01-2019

Oncoimmunology

Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival.

14-12-2018

Nature medicine

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.

01-11-2018

Clinical and translational radiation oncology

Retrospective methods to estimate radiation dose at the site of breast cancer development after Hodgkin lymphoma radiotherapy.

01-12-2017

International journal of epidemiology

Body mass index and breast cancer survival: a Mendelian randomization analysis.

01-12-2017

Oncotarget

PHIP - a novel candidate breast cancer susceptibility locus on 6q14.1.

28-11-2017

International journal of radiation oncology, biology, physics

Breast Cancer Risk After Radiation Therapy for Hodgkin Lymphoma: Influence of Gonadal Hormone Exposure.

15-11-2017

BMJ open

Long-term prognosis of young breast cancer patients (≤40 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study.

14-11-2017

Nature

Association analysis identifies 65 new breast cancer risk loci.

02-11-2017

International journal of cancer

Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium.

01-11-2017

Nature

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators.

07-09-2017

Cancer research

BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer.

01-06-2017

Cancer cytopathology

Human epididymis protein 4 immunostaining of malignant ascites differentiates cancer of Müllerian origin from gastrointestinal cancer.

01-03-2017

Oncotarget

Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21.

06-12-2016

Journal of medical genetics

PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS.

01-12-2016

Scientific reports

rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk.

15-11-2016

American journal of human genetics

Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation.

06-10-2016

Nature communications

Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration.

26-09-2016

International journal of cancer

Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer.

15-09-2016

Scientific reports

Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs).

07-09-2016

Human molecular genetics

An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression.

01-09-2016

PloS one

Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus.

25-08-2016

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers.

10-08-2016

The journal of pathology. Clinical research

High-throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium.

01-07-2016

Annals of oncology : official journal of the European Society for Medical Oncology

Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.

01-07-2016

Breast cancer research : BCR

Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus.

21-06-2016

Nature

Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

02-06-2016

Acta oncologica (Stockholm, Sweden)

Time trends in axilla management among early breast cancer patients: Persisting major variation in clinical practice across European centers.

01-06-2016

Nature genetics

Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170.

01-04-2016

Distinct Patterns of Myeloid Cell Infiltration in Patients With hrHPV-Positive and hrHPV-Negative Penile Squamous Cell Carcinoma: The Importance of Assessing Myeloid Cell Densities Within the Spatial Context of the Tumor.

An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer.

Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ.

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma.

Gene expression profiles of esophageal squamous cell cancers in Hodgkin lymphoma survivors versus sporadic cases.

Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial.

Comprehensive analysis of cutaneous and uveal melanoma liver metastases.

FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?†.

Transcriptome-wide association study of breast cancer risk by estrogen-receptor status.

Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses.

Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM).

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.

Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.

Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCIS.

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.

Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer.

Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma.

Concurrent Radiotherapy and Panitumumab after Lymph Node Dissection and Induction Chemotherapy for Invasive Bladder Cancer.

The circular RNome of primary breast cancer.

HLA class II expression on tumor cells and low numbers of tumor-associated macrophages predict clinical outcome in oropharyngeal cancer.

Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations.

Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival.

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.

Retrospective methods to estimate radiation dose at the site of breast cancer development after Hodgkin lymphoma radiotherapy.

Body mass index and breast cancer survival: a Mendelian randomization analysis.

PHIP - a novel candidate breast cancer susceptibility locus on 6q14.1.

Breast Cancer Risk After Radiation Therapy for Hodgkin Lymphoma: Influence of Gonadal Hormone Exposure.

Long-term prognosis of young breast cancer patients (≤40 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study.

Association analysis identifies 65 new breast cancer risk loci.

Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium.

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators.

BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer.

Human epididymis protein 4 immunostaining of malignant ascites differentiates cancer of Müllerian origin from gastrointestinal cancer.

Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21.

PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS.

rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk.

Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation.

Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration.

Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer.

Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs).

An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression.

Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus.

Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers.

High-throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium.

Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.

Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus.

Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Time trends in axilla management among early breast cancer patients: Persisting major variation in clinical practice across European centers.

Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170.

This site uses cookies

FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?^†.